Sartorius shares climbed 2% on Monday after a report said that Elliott Investment Management has assembled a position in the biopharma equipment supplier. The move was reported in the press and immediately corresponded with the uptick in Sartorius stock.
The same report indicated that Elliott has also taken a sizeable stake in Bio-Rad Laboratories. UBS is cited in the reporting as stating that Bio-Rad currently owns 28% of Sartorius, a holding that links the two companies in the ownership structure described.
According to the published account, Elliott intends to engage with Bio-Rad with the objective of improving Bio-Rad's stock price and unlocking value associated with its stake in Sartorius. The report further characterizes Elliott's view of Sartorius as a high-quality business that has solid growth prospects.
The information available in the report ties several elements together: a reported activist investment by Elliott, a reported substantial Bio-Rad ownership percentage in Sartorius as stated by UBS, and an asserted plan by Elliott to press Bio-Rad on stock performance and value realization related to Sartorius. Market participants reacted to those reports with a modest rise in Sartorius equity on the day the news was published.
The reporting does not provide additional details about the size of Elliott's holdings, timing of any proposed actions, or any planned specific measures to be taken by Elliott or by Bio-Rad. It also does not include responses from either Elliott or Bio-Rad within the account provided.
The sequence set out in the report links activist investment activity to potential corporate engagement intended to influence shareholder value. For market observers and participants in the biopharma equipment and laboratory supplies sectors, the developments reported draw attention to ownership dynamics and possible activist strategies, while leaving open the outcomes and timelines for any engagement or changes in corporate strategy or stock performance.
Summary of developments
- Sartorius shares rose 2% on Monday after reporting that Elliott Investment Management has built a stake in the company.
- Elliott is also reported to have taken a significant position in Bio-Rad Laboratories.
- UBS is cited as saying Bio-Rad owns 28% of Sartorius.
- The report states Elliott plans to press Bio-Rad to improve its stock price and to unlock value tied to Sartorius, and that Elliott views Sartorius as a high-quality business with strong growth prospects.